Figure 1From: Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancerVLC in tumor and normal tissues. FACS analysis of VLC in (A) Ficoll isolated tumor associated host cells and (B) normal tissues as indicated. CD45 stain is indicated on the X-axis and VE-Cadherin stain is indicated on the Y-axis.Back to article page